Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

A.J. Coles, C.L. Twyman, D.L. Arnold, J.A. Cohen, C. Confavreux, E.J. Fox, H.P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, T. Miller, E. Fisher, R. Sandbrink, S.L. Lake, D.H. Margolin, P. Oyuela, F. Barkhof, M.A. Panzara, D. Compston

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1829-1839
Issue number9856
Publication statusPublished - 2012

Cite this